Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan in High-Risk TA-TMA
NCT07347990Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Aug 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Iptacopan in thrombotic microangiopathy (TMA), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Started Aug 2026; status: recruiting.
02
Drugs
Iptacopan
03
Conditions
thrombotic microangiopathy (TMA)
Beyond the preview
Go deeper on NCT07347990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07347990.